Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20767619 | 0.99 | NPC1 (0.34) | NPC1DGAT1KLKB1 | |
| Hydrochloric Acid SCHEMBL29722941 | 0.99 | NPC1 (0.34) | NPC1DGAT1KLKB1 | |
| Hydrochloric Acid SCHEMBL20767618 | 0.97 | NPC1 (0.34) | NPC1DGAT1KLKB1 | |
| SCHEMBL19204030 | 0.87 | DGAT1 (0.40) | NPC1DGAT1KLKB1 | |
| SCHEMBL21751708 | 0.85 | DGAT1 (0.38) | NPC1DGAT1KLKB1 | |
| SCHEMBL29331059 | 0.78 | DGAT1 (0.41) | NPC1DGAT1KLKB1 | |
| SCHEMBL3305424 | 0.78 | DGAT1 (0.41) | NPC1DGAT1 | |
| SCHEMBL30542276 | 0.76 | DGAT1 (0.40) | NPC1DGAT1 | |
| SCHEMBL19203911 | 0.75 | DGAT1 (0.41) | NPC1DGAT1KLKB1 | |
| SCHEMBL20553711 | 0.75 | DGAT1 (0.37) | NPC1DGAT1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240425520-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC (US) | 2024-12-26 | — | — | US | disclosed |
| CN-114929689-B | Bcl-2 inhibitors | 百济神州有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-11993610-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-11903950-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2024-02-20 | — | — | US | disclosed |
| EP-3672976-B1 | BCL-2 INHIBITORS | GUANGZHOU LUPENG PHARMACEUTICAL COMPANY LTD (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | NEWAVE PHARMACEUTICAL INC. | 2023-09-21 | — | — | US | disclosed |
| CN-116621860-A | Bcl-2 inhibitors | 广州麓鹏制药有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-111511748-B | Bcl-2 inhibitors | 广州麓鹏制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-4110298-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-11365206-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210332065-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021066873-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-3672976-A1 | BCL-2 INHIBITORS | Newave Pharmaceutical Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200197406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2020-06-25 | — | — | US | disclosed |
| WO-2020041406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020041405-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2019040573-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | BCL2, BCL2L1, BCL2L2 | NPC1 2558/4885DGAT1 3779/4885KLKB1 3509/4885 |
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | NPC1 3788/4885DGAT1 4227/4885KLKB1 3570/4885 |
| US-11903950-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | NPC1 3788/4885DGAT1 4227/4885KLKB1 3570/4885 |
| US-11365206-B2 | BCL-2 inhibitors | BCL2, BCL2L10, BCL2L1 | NPC1 3290/4885DGAT1 4176/4885KLKB1 4149/4885 |
| US-20240425520-A1 | BCL-2 INHIBITORS | BCL2, BCL2L11, BCL2L10 | NPC1 3704/4885DGAT1 4414/4885KLKB1 3932/4885 |
| US-11993610-B2 | BCL-2 inhibitors | BCL2, BCL2L11, BCL2L10 | NPC1 3704/4885DGAT1 4414/4885KLKB1 3932/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | NPC1 3788/4885DGAT1 4227/4885KLKB1 3570/4885 |
| US-20200197406-A1 | BCL-2 INHIBITORS | BCL2, BCL2L10, BCL2L1 | NPC1 3290/4885DGAT1 4176/4885KLKB1 4149/4885 |
| US-20210332065-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | NPC1 3788/4885DGAT1 4227/4885KLKB1 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.